irinotecan has been researched along with Neoplasms, Squamous Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, TL; Hou, MH; Jain, V; Kuppusamy, R; Lee, TC; Lin, YW; Patel, AS; Su, TL | 1 |
| Hatayama, S; Honda, T; Kagabu, M; Kaido, Y; Kumagai, S; Miura, F; Morohara, Y; Murai, M; Omi, H; Satoh, A; Shoji, T; Sugiyama, T; Takatori, E; Yoshizaki, A | 1 |
| Bains, M; Campbell, J; Capanu, M; Ilson, DH; Kelsen, DP; Ku, GY; Minsky, BD; Rizk, N; Rusch, V; Shah, M; Tang, L | 1 |
| Iwai, T; Kawano, T; Miyake, S; Nagai, K; Nakajima, Y | 1 |
1 trial(s) available for irinotecan and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Neoplasms, Squamous Cell; Positron-Emission Tomography | 2012 |
3 other study(ies) available for irinotecan and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Squamous Cell; Neovascularization, Pathologic; Phthalazines; Small Cell Lung Carcinoma; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
[Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Humans; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Squamous Cell; Survival Rate; Uterine Cervical Neoplasms | 2010 |
CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
Topics: Blotting, Western; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Irinotecan; Neoplasms, Squamous Cell; RNA, Messenger; Tumor Cells, Cultured | 2001 |